Statistics for Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
Total visits
| views | |
|---|---|
| Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers | 259 |
Total visits per month
| views | |
|---|---|
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 0 |
| June 2025 | 0 |
| July 2025 | 0 |
File Visits
| views | |
|---|---|
| deBono_2017_phase.pdf | 609 |
| java.util.UUID:82bc90a8-5a71-45f4-b06b-9c769b08e189 | 100 |
| java.util.UUID:b876d5b8-248f-4591-9d2c-8b5e47ff43e6 | 18 |
| java.util.UUID:87750395-1f7d-4f91-9279-cb2ce98d63a5 | 5 |
Top country views
| views | |
|---|---|
| United States | 184 |
| Germany | 20 |
| Ukraine | 6 |
| Russia | 5 |
| United Kingdom | 4 |
| China | 3 |
| Portugal | 3 |
| Canada | 2 |
| Italy | 1 |
| Malaysia | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 51 |
| Fairfield | 24 |
| Houston | 15 |
| Cambridge | 14 |
| Kiez | 11 |
| Ann Arbor | 9 |
| Jacksonville | 7 |
| Gunzenhausen | 6 |
| Kiev | 6 |
| Porto | 3 |
| Saint Petersburg | 3 |
| Baltimore | 2 |
| Beijing | 2 |
| Kansas City | 2 |
| Newcastle Upon Tyne | 2 |
| Nürnberg | 2 |
| San Francisco | 2 |
| Toronto | 2 |
| Washington | 2 |
| Abingdon | 1 |
| Berlin | 1 |
| Bloomsbury | 1 |
| Brooklyn | 1 |
| El Segundo | 1 |
| Fort Worth | 1 |
| Milan | 1 |
| Moscow | 1 |
| New York | 1 |
| Philadelphia | 1 |
| Scottsdale | 1 |
| Seremban | 1 |
| Zheleznogorsk | 1 |